Compared to the control group, tumors treated with PTX/PEG2k-Fmoc-NLG had a higher percentage of CD8+ T cells that produced granzyme B. Synergistically, PTX’s tumoricidal properties combined with NLG’s immune-enhancing properties produced much greater anti-tumor effects [105]. Here, CD8A is linked to neoplasm.